Somatuline Autogel: an extended release lanreotide formulation.
Somatuline Autogel provides effective control of growth hormone levels and is at least as effective as intramuscular Somatuline LA. Somatuline Autogel has a first order kinetic profile providing at least 28 days' efficacy with reduced burst release and a more consistent drug release over the dose period. The product is presented in a pre-filled syringe and is given deep subcutaneously.
Lightman
Stafford
S
University of Bristol, Bristol Royal Infirmary, Bristol BS2 8HW.
D000172:Acromegaly / Q000188:drug therapy*; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002276:Carcinoid Tumor / Q000188:drug therapy*; D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations; D005260:Female; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D007271:Injections, Intradermal; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D010456:Peptides, Cyclic; D012307:Risk Factors; D013004:Somatostatin / Q000031:analogs & derivatives*
D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D015282:Octreotide